RT Journal Article
T1 Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment
A1 Delgado-Martín, Belén
A1 Medina, Miguel Ángel
K1 Cancer therapy
K1 Diagnostics
K1 Glioblastoma
K1 Patient stratification
K1 Diagnóstico
K1 Neoplasias
K1 Preparaciones farmacéuticas
K1 Terapéutica
K1 Encéfalo
AB Gliomas are the most common primary brain tumors in adults. They arise in the glial tissue and primarily occur in the brain. Low-grade tumors of World Health Organization (WHO) grade II tend to progress to high-grade gliomas of WHO grade III and, eventually, glioblastoma of WHO grade IV, which is the most common and deadly glioma, with a median survival of 12-15 months after final diagnosis. Knowledge of the molecular biology and genetics of glioblastoma has increased significantly in the past few years, giving rise to classification methods that can help in management and stratification of glioblastoma patients. However, glioblastoma remains an incurable disease. Glioblastoma cells have acquired genetic and metabolic adaptations in order to sustain tumor growth and progression, including changes in energetic metabolism, invasive capacity, migration, and angiogenesis, that make it very difficult to find suitable therapeutic targets and to develop effective drugs. The current standard of care for glioblastoma patients is surgery followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide. Although progress in glioblastoma therapies in recent years has been more limited than in other tumors, numerous drugs and targets are being proposed and many clinical trials are underway to develop effective subtype-specific treatments.
PB Wiley
YR 2020
FD 2020-03-12
LK http://hdl.handle.net/10668/3649
UL http://hdl.handle.net/10668/3649
LA en
NO Delgado-Martín B, Medina MA. Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. Adv Sci. 2020 Mar 12;7(9):1902971
DS RISalud
RD Apr 8, 2025